Pharmaceutical stocks opened on a strong note on Tuesday, with several leading companies witnessing sharp gains.
Aurobindo Pharma surged 4.05% to ₹1,190.95, leading the sectoral rally and attracting strong investor interest.
Lupin jumped 3.81% to ₹2,102.40, continuing its recent upward trend driven by positive earnings expectations.
Biocon climbed 2.80% to ₹365.90, as the company benefits from strong demand for biosimilars and regulatory approvals.
Divi’s Laboratories gained 2.51% to ₹6,119.80, reflecting confidence in its specialty API segment growth.
Cipla rose 2.43% to ₹1,484.45, with investors optimistic about its expanding product pipeline and US market traction.
Dr. Reddy’s Laboratories advanced 2.02% to ₹1,240.35, supported by strong export growth and recent product launches.
Zydus Lifesciences was up 1.60% at ₹948.95, riding on expectations of new drug approvals and steady domestic demand.
Sun Pharma added 1.58% to trade at ₹1,720.55, continuing its momentum in specialty generics and dermatology segments.
Abbott India gained 1.37% to ₹29,173.45, as the company maintains steady growth in its premium healthcare portfolio.
Torrent Pharmaceuticals was up 1.15% at ₹3,095.15, benefiting from increasing traction in the cardiovascular and diabetes segments.
Glenmark Pharmaceuticals rose 1.08% to ₹1,421.30, as investors anticipate a positive growth outlook from its branded generics business.
GlaxoSmithKline Pharmaceuticals edged up 1.13% to ₹2,053.45, supported by its continued expansion in vaccines and respiratory therapies.
Ipca Laboratories climbed 0.65% to ₹1,429.00, reflecting investor confidence in its domestic formulations and API business.
Mankind Pharma traded higher at ₹2,436.30, up 0.57%, with steady demand in its consumer healthcare and prescription drug segments.
Alkem Laboratories gained 0.51% to ₹4,732.65, amid optimism about its growth in anti-infectives and pain management drugs.
The broad-based rally in pharma stocks is driven by positive earnings expectations, expansion in global markets, and increasing demand for key therapies. Investors are keenly watching upcoming regulatory developments and earnings reports, which could further influence market sentiment.
Disclaimer: This article is for informational purposes only and does not constitute financial advice. Investors should consult their financial advisors before making any investment decisions.
